NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Browsing: Resource

The Rockefeller Foundation has taken leadership on developing strategies to deal with COVID-19. They have created the position of Managing Director, Pandemics and appointed and expert in the field, Dr.  Jonathan “Jono” Quick MD to fill the position. Quick is author of a book entitled “End of Pandemics.” They also have funded an initiative at Arizona State University called The COVID-19 Diagnostics Commons to build a comprehensive database on testing resources. And they have funded a national action plan, the National COVID-19 Testing and Tracing Plan which is described below. Pandemics sicken and kill people in three ways: first by…

Ending Pandemics.  Rockefeller Foundation is taking a leadership role in addressing the Pandemic,  putting lots of money in and bringing in an individuals with good credentials and a plan as outlined in his 2018 book. Jonathan Quick MD. What is interesting that so many had predicted this.  Had our leaders been heeding the warnings in this book, the ravages of COVID might not have happened. It is clear were we were woefully unprepared. Dr. Quick has identified 7 things that if done, we all live happy together. If we don’t he paints a grim picture, pointing out that we are…

The Washington Post has produced an exceptional work on vaccines and their progress.  It does a wonderful job describing the complexity of vaccine development using infographics. Some of the key points. Researchers in the United States set an audacious goal in January to develop a coronavirus vaccine within 12 to 18 months. This would be a world record. The mumps vaccine is considered to be the fastest to move, in four years, from scientific concept to approval in 1967. The quest for an HIV vaccine continues, 36 years and counting. Coronavirus vaccines are moving much faster, partly because governments are taking on the…

ASU, World Economic Forum and the Rockefeller Foundation partner help companies get back to work through a new initiative :The COVID-19 Diagnostics Commons — an interactive hub for the global community to access the very latest information about testing options and to share knowledge and practices for safely bringing back and keeping employees in the workplace during the COVID-19 era. Real-world, timely and accessible data on workplace reopening, testing and employee safety initiatives is needed to get the global economy back on track. To that end, two critical resources are now available: The COVID-19 Workplace Commons, which collects and disseminates…

FasterCures, a center of the Milken Institute, is currently tracking the development of treatments and vaccines for COVID-19 (coronavirus). This tracker contains an aggregation of publicly-available information from validated sources. According to Milken there are:  316 Treatments in 7 categories are being developed now.  212 Vaccines in development in 9 categories.  34 of which are now in testing.  The leading vaccine candidates as of mid September 2020 are listed here. 

Market Overview was prepared by a team from Cambridge University. The objective was understanding of the testing market in Europe. The report also offers insight into Asia.  The 50 page deck examined the COVID testing market broadly and assessed a variety of market dynamics: Market size for PCR and Antibody tests The different business models employed  Regulatory pathways  Supply chain analysis including bottlenecks. Regulatory landscape.  Including a detailed flow chart analyzing zing the complexity of approval process in the EU, China and South Korea.  Also included was the commercialization landscape and the reimbursement analysis for France, Germany, UK, Spain and…

The Bill & Melinda Gates Foundation, Wellcome, and Mastercard today committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. “Viruses like COVID-19 spread rapidly, but the development of vaccines and treatments to stop them moves slowly,” said Mark Suzman, chief executive officer of the Bill & Melinda Gates Foundation. “If we…